CONCLUSIONS in patients with a recent acute coronary syndrome, rivaroxaban reduced the risk of the composite end point of death from cardiovascular causes, myocardial infarction, or stroke.
结论在近期有过一次急性冠脉综合征的患者中,利伐沙班降低了包括心血管原因所致死亡、心肌梗死或卒中的复合终点的发生危险。
Main Outcome Measures The primary end point was a composite of initial fatal or nonfatal coronary event or stroke or revascularization.
复合终点为初次致命或非致命性冠状动脉事件、卒中和血管重建。
All patients were followed for the composite outcome of cardiovascular death, mi, unstable angina requiring hospitalization, stroke, or transient ischemic attack.
对所有患者进行随访,观察心血管死亡、心肌梗死、需要住院治疗的不稳定型心绞痛、卒中或短暂性脑缺血的混合事件发生情况。
应用推荐